Ischemic Stroke. Cerebral infarction due to thrombosis of cerebral arteries
Conditions
Interventions
Intervention 1: 20% Vial Albumin 1 geram per kiloogram Body Weight infusion during 2 hours Single Dose. Intervention 2: Plasebo Vial as a Same Dose of Albumin.
Treatment - Drugs
Placebo
20% Vial Albumin 1 geram per kiloogram Body Weight infusion during 2 hours Single Dose
Plasebo Vial as a Same Dose of Albumin
Sponsors
JondiShapur Ahvaz university of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 83 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with acute ischemic stroke; age between 18 to 83 years old; NIH stroke scale more than 5; transfusion of albumin with in 5 hour and infarction in MCA area. Exclusion criteria: heart failure(CHF) in 6 last months; concurrent valvular heart disease with CHF; stenosis of aorta or aortic valve; open heart surgery; acute MI in last 6 month; MI symptoms; Troponin increase in hospitalization (>0.1mcg/l); doubt of aorta dakshin in hospitalization; acute heart arythmia cause of hemodynamic transience; physical examination results include: JVP>4cm on top of sternal angle S3, Tachycardia in relaxation cause Congestive Heart failure (HR>100/min), hepatojugular abnormal reflex specific C-xray of Pulmonary edema Pitting edema of the lower extremities that can cause congestive heart failure; acute or chronic lung disease requiring supplemental oxygen therapy is intermittent or permanent; fever T>37.5; serum creatinine > 2 mg / dl.; excessive dehydration; evidence of cerebral hemorrhage on CT or MRI (Intracranial hematoma / SAH / epidural hemorrhage / acute or chronic subdural hematoma); allergy to albumin 17.Allery to latex; Hgb < 7.5 g / dl; pregnancy / lactation / positive pregnancy test (women of childbearing age have a negative test for pregnancy before albumin administration ); medical evidence of any serious or life-threatening condition that interfere with 3-month follow-up trial or assessing patients'outcome or Treatment with the contraindica albumin is harmful; participation in another clinical trial data yet; occurrence of stroke due to complications of hospitalization for other conditions or complications due to a procedure; not afford to buy albumin and lacunar Infarction.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient Functional Outcome. Timepoint: At admission time,after one week and after 3 month. Method of measurement: Barthel Scale, Modified Rankin Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Morbidity and Mortality. Timepoint: At the admision, after one week and 3 month. Method of measurement: Registration of mortality.;Drug side effects. Timepoint: At the admision,after one week and 3 month. Method of measurement: Drug side effects chart. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Hemmati, MD
JondiShapurAhvaz University of Medical Sciences
Outcome results
None listed